Beyond Appetite: Extrahepatic RNAi to Transform Obesity & Metabolic Disease – Dual siRNA Reprogramming Fat for Durable, Muscle- Enhancing Weight Loss
- Exploring advances in extrahepatic dual RNAi delivery to enable targeted delivery to adipose tissue for treating the root cause of metabolic disease
- Demonstrating preclinical efficacy through human adipocyte validation to provide robust proof-of-concept and de-risk clinical translation
- Discussing how dual-target RNAi can expand beyond obesity into MASLD/MASH and cardiometabolic health to systemically improve metabolic parameters
- Positioning multi-target RNAi as the next wave beyond appetite suppression to move beyond the limitations of central appetite suppression and offer a more durable, tissue-specific, and holistic solution for sustainable weight loss